Landos Biopharma, Inc. LABP
Set alert
At close · May 23
52-week range unavailable
- Open
- 22.93
- Prev close
- 22.93
- Mkt cap
- 71.68M
- Vol
- 50.90K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 22.75
- High
- 22.94
- Forward P/E
- -11.08
- Beta
- 0.00
- Short ratio
- 0.08
- Inst. own
- 52.04%
- Dividend
- 0.00
- Ex-div date
- Earnings
- May 9, 2024
- 50-d avg
- 20.19
- 200-d avg
- 8.35
- 1y target
- 12.71
Key statistics
- Market cap
- 71.68M
- Enterprise value
- 42.67M
- Trailing P/E
- 0.00
- Forward P/E
- -11.08
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 3.09
- EPS (TTM)
- -4.00
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -12.13M
- Total cash
- 29.00M
- Total debt
- 0
- Return on equity
- -70.67%
- Shares outstanding
- 3.13M
- Short % of float
- 0.09%
- 50-day average
- 20.19
- 200-day average
- 8.35
Analyst view
Consensus: hold
- Target (low)
- 5.00
- Target (mean)
- 12.71
- Target (high)
- 20.42
Next earnings
May 9, 2024
Expected May 9, 2024. Consensus EPS estimate -0.63.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 9, 2024 | Mar 1, 2024 | -1.00 | — | — | — |
| Mar 21, 2024 | Dec 1, 2023 | -0.91 | — | — | — |
| Nov 9, 2023 | Sep 1, 2023 | -0.79 | — | — | — |
| Aug 9, 2023 | Jun 1, 2023 | -1.10 | — | — | — |
| May 12, 2023 | Mar 1, 2023 | -1.00 | — | — | — |
| Mar 23, 2023 | Dec 1, 2022 | -1.50 | — | — | — |
About Landos Biopharma, Inc.
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate is NX-13, an oral gut-selective Nucleotide Oligomerization Domain (NLRX1), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines that is in Phase 2 clinical trial to treat ulcerative colitis (UC) and completed Phase 1 to treat Crohn's disease (CD). The company's preclinical candidates in development include LABP-73, an oral and small molecule NLRX1 pathway agonist for the treatment of asthma and eosinophilic disorders; LABP-66 is an oral and small molecule NLRX1 pathway agonist for the treatment of multiple sclerosis and neurodegenerative disorders; and LABP-69, an oral PLXDC2 agonist for the treatment of rheumatoid arthritis, UC, and CD. The company has a license and collaboration agreement with LianBio Respiratory Limited to develop, manufacture, and commercialize omilancor and NX-13. Landos Biopharma, Inc. was incorporated in 2017 and is headquartered in Blacksburg, Virginia. As of May 23, 2024, Landos Biopharma, Inc. operates as a subsidiary of AbbVie Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- landosbiopharma.com
News
- AbbVie Completes Acquisition of Landos Biopharma
- LANDOS BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Landos Biopharma, Inc. - LABP
- Stockholder Alert: Ademi LLP continues Investigation of the Fairness of Landos Biopharma, Inc.'s transaction with AbbVie
- LANDOS BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Landos Biopharma, Inc. - LABP
- STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Landos Biopharma, Inc - LABP
- Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
- Why Is Landos Biopharma (LABP) Stock Up 168% Today?
- Shareholder Alert: Ademi LLP investigates whether Landos Biopharma, Inc. has obtained a Fair Price in its transaction with AbbVie
- LABP Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Landos Biopharma, Inc. Is Fair to Shareholders
- AbbVie to buy Landos to expand pipeline of immunity-related illnesses
Your note
Sign in to keep a note on LABP — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BASSAGANYA-RIERA JOSEP | Beneficial Owner of more than 10% of a Class of Security | Sale | Feb 27, 2023 | 0 |
| CHAUHAN JYOTI | Officer | Conversion of Exercise of derivative security | Jul 25, 2021 | 209,299 |
| PERCEPTIVE ADVISORS, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Feb 8, 2021 | 0 |
| POUKALOV KONSTANTIN | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Feb 8, 2021 | 0 |
| RTW INVESTMENTS, L.P. | Beneficial Owner of more than 10% of a Class of Security | Sale | Sep 22, 2022 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Perceptive Advisors Llc | 47.71% | 1,486,991 | 6.26M | Jun 29, 2023 |
| Tower Research Capital LLC (TRC) | 0.05% | 1,542 | 6.49K | Jun 29, 2023 |
| Royal Bank of Canada | 0.02% | 612 | 2.57K | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Delaware Group Equity Fds IV-Delaware Healthcare Fund | 0.47% | 14,718 | 61.92K | Jun 29, 2023 |
| Fidelity Extended Market Index Fund | 0.11% | 3,482 | 9.61K | May 30, 2023 |
| Vanguard Extended Market Index Fund | 0.08% | 2,399 | 10.09K | Jun 29, 2023 |
| Fidelity NASDAQ Composite Index Fund | 0.07% | 2,305 | 6.36K | May 30, 2023 |
| Fidelity Series Total Market Index Fund | 0.07% | 2,067 | 5.70K | May 30, 2023 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.07% | 2,098 | 8.83K | Jun 29, 2023 |